Free Trial

ConvaTec Group (LON:CTEC) Trading 6.9% Higher - Time to Buy?

ConvaTec Group logo with Medical background

Key Points

  • ConvaTec Group's stock rose 6.9% to GBX 247.12 ($3.33) on Wednesday, despite a 4% decline in trading volume compared to its average.
  • Analysts have set new price targets for the stock, with an average target of GBX 308 and four analysts rating it as a "Buy."
  • Insider Karim Bitar sold 1,250,000 shares of the company's stock at an average price of GBX 227, totaling £2,837,500.
  • Five stocks to consider instead of ConvaTec Group.

ConvaTec Group PLC (LON:CTEC - Get Free Report)'s share price rose 6.9% on Wednesday . The company traded as high as GBX 249.69 ($3.36) and last traded at GBX 247.12 ($3.32). Approximately 13,084,437 shares changed hands during trading, a decline of 4% from the average daily volume of 13,697,891 shares. The stock had previously closed at GBX 231.20 ($3.11).

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Royal Bank Of Canada upgraded ConvaTec Group to an "outperform" rating and decreased their price objective for the company from GBX 320 to GBX 315 in a research note on Thursday, August 21st. Peel Hunt restated an "add" rating and issued a GBX 280 price target on shares of ConvaTec Group in a research report on Tuesday, July 29th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a GBX 315 price objective on shares of ConvaTec Group in a research report on Wednesday, July 30th. Berenberg Bank dropped their target price on ConvaTec Group from GBX 335 to GBX 330 and set a "buy" rating on the stock in a report on Tuesday, August 19th. Finally, JPMorgan Chase & Co. reaffirmed an "overweight" rating on shares of ConvaTec Group in a report on Wednesday, July 30th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of GBX 309.40.

Get Our Latest Research Report on CTEC

ConvaTec Group Stock Down 3.8%

The company has a current ratio of 2.26, a quick ratio of 0.96 and a debt-to-equity ratio of 85.32. The firm has a 50 day moving average price of GBX 251.70 and a 200-day moving average price of GBX 258.25. The firm has a market cap of £5.93 billion, a price-to-earnings ratio of 39.24, a P/E/G ratio of 0.93 and a beta of 0.64.

Insider Activity at ConvaTec Group

In other ConvaTec Group news, insider Karim Bitar sold 1,250,000 shares of ConvaTec Group stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of GBX 227, for a total value of £2,837,500. 19.65% of the stock is currently owned by company insiders.

About ConvaTec Group

(Get Free Report)

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns.

Recommended Stories

Should You Invest $1,000 in ConvaTec Group Right Now?

Before you consider ConvaTec Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ConvaTec Group wasn't on the list.

While ConvaTec Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.